Evidence map›Paper›PMID 39977708›Full record

ArticleJCO clinical cancer informatics2025

Radiomics and Deep Learning Prediction of Immunotherapy-Induced Pneumonitis From Computed Tomography.

David S Smith, Levente Lippenszky, Michele L LeNoue-Newton, Neha M Jain, Kathleen F Mittendorf, Christine M Micheel, Patrick A Cella, Jan Wolber, Travis J Osterman

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. [Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis 
of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David S SmithInstitute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-1615-2231
Levente LippenszkyScience and Technology Organization, Artificial Intelligence & Machine Learning, GE HealthCare, Budapest, Hungary.ORCID 0009-0000-7835-2071
Michele L LeNoue-NewtonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3469-3784
Neha M JainVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Kathleen F MittendorfVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1097-9171
Christine M MicheelVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-7744-9039
Patrick A CellaPharmaceutical Diagnostics, GE HealthCare, Chalfont St Giles, United Kingdom.ORCID 0009-0006-4333-1178
Jan WolberPharmaceutical Diagnostics, GE HealthCare, Chalfont St Giles, United Kingdom.
Travis J OstermanVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2841-8121

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
NCATS NIH HHS UL1 TR000445
6 · The paper itself

Abstract

purposePrimary barriers to application of immune checkpoint inhibitor (ICI) therapy for cancer include severe side effects (such as potentially life threatening pneumonitis [PN]), which can cause the discontinuation of treatment. Predicting which patients may develop PN while on ICI would improve both safety and potential efficacy because treatments could be safely administered for longer or discontinued before severe toxicity.

methodsStarting from a cohort of 3,351 patients with cancer who received previous ICI therapy at the Vanderbilt University Medical Center, we curated 2,700 contrast chest computed tomography (CT) volumes for 671 patients. Three different pure imaging models predicted the potential for PN using only a single time point before the first ICI dose.

resultsThe first model used 109 radiomics features only and achieved an AUC of 0.747 (CI, 0.705 to 0.789) with a positive predictive value (PPV) of 0.244 (CI, 0.211 to 0.276) at a sensitivity of 0.553 (CI, 0.485 to 0.621) using mainly features describing the global lung properties. The second model used a convolutional neural network (CNN) on the raw CTs to improve to an AUC of 0.819 (CI, 0.781 to 0.857) with a PPV of 0.244 (CI, 0.203 to 0.284) at a sensitivity of 0.743 (CI, 0.681 to 0.806). The third model combined both radiomics and deep learning but, with an AUC of 0.829 (CI, 0.797 to 0.862) and a PPV of 0.254 (CI, 0.228 to 0.281) at a sensitivity of 0.780 (CI, 0.721 to 0.840), did not show a significant improvement on the CNN-only model.

conclusionThis new model suggests the utility of deep learning in PN prediction over traditional pure radiomics and promises better management for patients receiving ICI and the ability to better stratify patients in immunotherapy drug trials.

Indexed as

Deep LearningImmune Checkpoint InhibitorsImmunotherapyNeoplasmsPneumoniaTomography, X-Ray ComputedAgedFemaleHumansMaleMiddle AgedRadiomicsImmune Checkpoint Inhibitors

Identifiers

PMID39977708
PMCPMC11867800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.